Literature DB >> 20657553

Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma.

Mei-Chi Hsu1, Jenn-Ren Hsiao, Kung-Chao Chang, Yuan-Hua Wu, Ih-Jen Su, Ying-Tai Jin, Yao Chang.   

Abstract

Intratumoral cytotoxic T lymphocytes are critical for controlling tumor recurrence, and programmed death-1 (PD-1) is a recognized marker of T-cell dysfunction. We analyzed this marker and its binding ligands in nasopharyngeal tumor tissue and non-cancerous nasopharyngeal control tissue to retrospectively evaluate the correlation between its expression and the post-treatment outcome of nasopharyngeal carcinoma patients. Using double immunofluorescence staining, we found that the expression of PD-1 in CD8 T cells in tumor tissue was significantly higher than in control tissue (mean: 28.4 vs 3.9%, P<0.0001). Although the expression rate of PD-1 in intratumoral CD8 cells was not associated with the other clinicopathological parameters examined, the higher expression rate in this subset of T cells significantly correlated with a poorer prognosis of overall survival, disease-free survival, and locoregional recurrence-free survival of the cancer patients (P=0.05, 0.007, and 0.004, respectively). Multivariate analysis confirmed it as an independent risk factor for death, treatment failure, and local recurrence of nasopharyngeal carcinoma. On the other hand, the expression of PD-1 in CD4 T cells and of its ligands in epithelial and stromal cells was not significantly different between tumor and control tissue, and its expression was not associated with clinical outcome of the cancer patients. We propose that PD-1 expression in CD8 cells reflects the selective suppression of cytotoxic lymphocytes in the tumor microenvironment and predicts recurrence of nasopharyngeal carcinoma after conventional therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20657553     DOI: 10.1038/modpathol.2010.130

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  60 in total

Review 1.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

3.  Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

Authors:  Yuki Honda; Atsushi Otsuka; Sachiko Ono; Yosuke Yamamoto; Judith A Seidel; Satoshi Morita; Masahiro Hirata; Tatsuki R Kataoka; Tatsuya Takenouchi; Kazuyasu Fujii; Takuro Kanekura; Yuko Okubo; Kenzo Takahashi; Teruki Yanagi; Daichi Hoshina; Hiroo Hata; Riichiro Abe; Taku Fujimura; Takeru Funakoshi; Koji Yoshino; Mamiko Masuzawa; Yasuyuki Amoh; Ryota Tanaka; Yasuhiro Fujisawa; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-11-04       Impact factor: 8.110

4.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.

Authors:  Jaemoon Koh; Heounjeong Go; Bhumsuk Keam; Moon-Young Kim; Soo Jeong Nam; Tae Min Kim; Se-Hoon Lee; Hye Sook Min; Young Tae Kim; Dong-Wan Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Mod Pathol       Date:  2015-07-17       Impact factor: 7.842

Review 5.  AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.

Authors:  Cory D Fulcher; Missak Haigentz; Thomas J Ow
Journal:  Head Neck       Date:  2017-11-24       Impact factor: 3.147

6.  PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

Authors:  Evan J Lipson; Jeremy G Vincent; Myriam Loyo; Luciane T Kagohara; Brandon S Luber; Hao Wang; Haiying Xu; Suresh K Nayar; Timothy S Wang; David Sidransky; Robert A Anders; Suzanne L Topalian; Janis M Taube
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

7.  Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors:  Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-29       Impact factor: 4.553

8.  Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.

Authors:  E Muraro; E Vaccher; C Furlan; E Fratta; G Fanetti; D A Fae'; D Martorelli; M Cangemi; J Polesel; F Navarria; C Gobitti; E Comaro; C Scaini; C Pratesi; S Zanussi; V Lupato; G Grando; V Giacomarra; S Sulfaro; L Barzan; R Dolcetti; A Steffan; V Canzonieri; G Franchin
Journal:  Pathol Oncol Res       Date:  2020-06-21       Impact factor: 3.201

9.  Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma.

Authors:  Tao Xu; Zheli Huang; Bojin Su; Sumei Wang; Donghui Wang; Chunhua Wang; Weihong Wei; Jun Jiang; Guoyi Zhang; Huiling Yang; Weihan Hu
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

Review 10.  Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.

Authors:  Michael A Postow; James Harding; Jedd D Wolchok
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.